Get startedLog in
    Picture of Dynavax Technologies logo

    DVAX — Dynavax Technologies News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedMid CapHigh Flyer
    All News

    Brief: Dynavax Says Z-1018 Showed Lower Solicited Local & Systemic Post-Injection Reactions Vs Shingrix In Study

    Picture of Dynavax Technologies logoDynavax Technologies
    21/08/2025 13:00
    Aug 21 (Reuters) - Dynavax Technologies Corp DVAX.O:

DYNAVAX TECHNOLOGIES: IN PART 1 OF PHASE 1/2 CLINICAL TRIAL, Z-1018 WAS WELL-TOLERATED WITH FAVORABLE TOLERABILITY PROFILE

DYNAVAX TECHNOLOGIES: IN TRIAL Z-1018 SHOWED LOWER SOLICITED LOCAL & SYSTEMIC POST-INJECTION REACTIONS VERSUS SHINGRIX

DYNAVAX TECHNOLOGIES: IN TRIAL Z-1018 DEMONSTRATED ROBUST IMMUNE RESPONSES IN ALL DOSE ARMS

DYNAVAX TECHNOLOGIES: PART 2 OF PHASE 1/2 TRIAL WITH OPTIMAL DOSE OF Z-1018 FOR ADULTS 70 YEARS & OLDER EXPECTED TO START IN H2

Source text: [ID:]

Further company coverage: DVAX.O

 ((Reuters.Briefs@thomsonreuters.com;;))

    Recent news on Dynavax Technologies

    See all news